Rockwell Medical (NASDAQ:RMTI) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Rockwell Medical (NASDAQ:RMTI) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Other equities research analysts have also issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rockwell Medical in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $2.50 price target on shares of Rockwell Medical in a report on Monday, January 26th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Rockwell Medical presently has a consensus rating of “Hold” and an average price target of $2.50.

Rockwell Medical Stock Performance

RMTI stock opened at $0.87 on Friday. The company has a quick ratio of 3.50, a current ratio of 3.91 and a debt-to-equity ratio of 0.25. The firm has a market cap of $34.29 million, a PE ratio of -5.80 and a beta of 1.71. The business has a 50 day moving average of $1.01 and a 200-day moving average of $1.05. Rockwell Medical has a 12-month low of $0.78 and a 12-month high of $2.10.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). Rockwell Medical had a negative return on equity of 16.11% and a negative net margin of 7.67%.The business had revenue of $18.35 million for the quarter, compared to the consensus estimate of $18.58 million. As a group, sell-side analysts expect that Rockwell Medical will post 0.03 earnings per share for the current year.

Institutional Trading of Rockwell Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in RMTI. Panagora Asset Management Inc. purchased a new stake in Rockwell Medical during the 2nd quarter worth about $41,000. XTX Topco Ltd grew its holdings in Rockwell Medical by 286.5% during the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after buying an additional 46,029 shares in the last quarter. Jane Street Group LLC purchased a new position in Rockwell Medical during the 4th quarter valued at about $84,000. GSA Capital Partners LLP increased its position in shares of Rockwell Medical by 635.1% during the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after buying an additional 141,672 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Rockwell Medical by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after buying an additional 41,668 shares during the period. 23.31% of the stock is currently owned by institutional investors.

Trending Headlines about Rockwell Medical

Here are the key news stories impacting Rockwell Medical this week:

• Positive Sentiment: Achieved adjusted EBITDA profitability for the second straight year, showing improved operating leverage that can support the path to sustainable profitability. Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results
• Positive Sentiment: Featured in Zacks screens as a value/momentum candidate — this can attract bargain hunters and momentum traders looking for turnaround stories. Should Value Investors Buy Rockwell Medical (RMTI) Stock?
• Neutral Sentiment: Full Q4 earnings call/transcript provides management commentary and color on drivers of the quarter and the FY26 outlook — useful for investors who want to hear management’s execution plan and assumptions. Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed revenue estimates and reported EPS came in below some consensus figures, signaling slower top?line momentum; several outlets flagged the revenue decline as the main driver of investor concern. Rockwell Medical (RMTI) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Management’s cost?cutting/right?sizing plan has raised execution risk and could pressure future growth if not managed carefully — analysts flagged this as a demand/execution risk that may weigh on investor confidence. Rockwell Medical’s Cost Cuts Raise Execution Risk and Threaten Future Growth Prospects
• Negative Sentiment: Company issued a FY26 outlook that some market coverage characterized as cautious after the quarter; investors typically punish missed top?line results and uncertain guidance more than one?time positives. Rockwell Medical misses top-line estimates; gives FY26 outlook

About Rockwell Medical

Rockwell Medical, Inc is a Delaware?domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.